Danaher Co. (NYSE:DHR) Shares Purchased by Connable Office Inc.

Connable Office Inc. grew its stake in shares of Danaher Co. (NYSE:DHR) by 0.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,130 shares of the conglomerate’s stock after purchasing an additional 53 shares during the quarter. Connable Office Inc.’s holdings in Danaher were worth $3,928,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Benjamin Edwards Inc. lifted its stake in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after buying an additional 38 shares during the last quarter. Wedge Capital Management L L P NC boosted its stake in Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares during the period. Patrick M Sweeney & Associates Inc. grew its position in Danaher by 3.4% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares during the last quarter. Trust Co of Kansas raised its holdings in shares of Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after buying an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. boosted its position in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after buying an additional 40 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR opened at $239.45 on Friday. Danaher Co. has a 12-month low of $204.15 and a 12-month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $172.95 billion, a P/E ratio of 45.70, a PEG ratio of 4.44 and a beta of 0.85. The stock has a fifty day moving average of $263.42 and a 200-day moving average of $260.64.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.02 EPS. Equities analysts forecast that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is 20.61%.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 18.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of several analyst reports. KeyCorp raised their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. TD Cowen raised their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Leerink Partners raised their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Stifel Nicolaus upped their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.